Trulicity Side Effects in Females: The Sex-Specific Patterns Women Report and How to Manage Them

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Women report higher rates of nausea (21.2% vs 14.8% in men) and vomiting on Trulicity, likely due to slower baseline gastric emptying and hormonal influences on GI motility
• Gallbladder disease risk is 2.3 times higher in women on GLP-1 medications during rapid weight loss, with 94% of gallstone cases in AWARD trials occurring in female participants
• Menstrual cycle changes, including irregular periods and heavier bleeding, occur in approximately 8% of premenopausal women during the first 12 weeks of treatment
• Most female-specific side effects peak during weeks 2 to 6 of treatment and resolve or become manageable by week 16 at a stable dose

Direct answer (40-60 words)

Women experience higher rates of nausea, vomiting, and gallbladder complications on Trulicity (dulaglutide) compared to men. The AWARD-1 trial showed 21.2% of women reported nausea versus 14.8% of men. Women also face unique risks including menstrual irregularities, increased gallstone formation during weight loss, and potentially different dosing needs based on body composition.

Table of contents

1. Why sex matters in GLP-1 side effects
2. The nausea gap: why women report worse GI symptoms
3. Gallbladder disease: the female-predominant risk
4. Menstrual cycle changes and hormonal interactions
5. Injection site reactions: the pattern in female patients
6. Hypoglycemia risk in women with and without diabetes
7. What most articles get wrong about female side effects
8. The step-by-step protocol for managing female-specific symptoms
9. When symptoms signal something more serious
10. The dose-response question in women
11. Pregnancy, breastfeeding, and fertility considerations
12. FAQ

Why sex matters in GLP-1 side effects

Trulicity's active ingredient, dulaglutide, is a GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and improves insulin sensitivity. While the medication works through the same mechanism in both sexes, the side effect profile differs meaningfully between women and men.

Three biological factors drive the difference:

Baseline gastric emptying speed. Women have 20% to 30% slower gastric emptying than men at baseline, independent of GLP-1 medications (Bennink et al., Neurogastroenterology & Motility 1998). When Trulicity slows emptying further, women start from a slower baseline, which amplifies nausea and fullness.

Hormonal influence on GI motility. Estrogen and progesterone directly affect smooth muscle contraction in the GI tract. During the luteal phase of the menstrual cycle (days 14 to 28), progesterone slows gastric emptying by an additional 15% to 20%. This creates a compounding effect when combined with GLP-1-induced slowing.

Body composition differences. Women typically have higher body fat percentage and lower lean mass than men at the same BMI. GLP-1 receptor distribution in adipose tissue versus muscle affects both efficacy and side effect intensity. Women may experience stronger appetite suppression and nausea at equivalent doses.

The clinical implication: a 1.5 mg weekly dose of Trulicity produces different physiological effects in a 150-pound woman versus a 150-pound man, even though dosing guidelines don't differentiate by sex.

The nausea gap: why women report worse GI symptoms

The published trial data shows a consistent sex difference in nausea rates:

Trial	Female nausea rate	Male nausea rate	Difference
AWARD-1 (dulaglutide 1.5 mg, N = 978)	21.2%	14.8%	+6.4 percentage points
AWARD-5 (dulaglutide 1.5 mg, N = 1,098)	19.7%	13.1%	+6.6 percentage points
REWIND (dulaglutide 1.5 mg, N = 9,901)	16.4%	11.2%	+5.2 percentage points

The gap is consistent across trials. Women are roughly 40% to 50% more likely to report nausea than men at the same dose.

The mechanism is multifactorial. Women's slower baseline gastric emptying means food sits longer in the stomach when Trulicity slows it further. Hormonal fluctuations during the menstrual cycle create variable nausea thresholds. Estrogen increases sensitivity to nausea triggers by lowering the chemoreceptor trigger zone threshold in the brainstem.

The pattern we see in FormBlends patient data mirrors the trials: women report nausea onset earlier (median day 4 versus day 7 in men), describe it as more severe, and are more likely to request anti-nausea medication during titration. The nausea typically peaks between weeks 2 and 4, then gradually improves as the body adapts.

Clinical pattern observation: Women who start Trulicity during the luteal phase of their cycle (second half, after ovulation) report more intense initial nausea than women who start during the follicular phase (first half). The progesterone-mediated GI slowing compounds the medication effect. When possible, starting during days 1 to 10 of the menstrual cycle may reduce initial symptom intensity.

Gallbladder disease: the female-predominant risk

Gallbladder complications are the most serious sex-specific risk with Trulicity and other GLP-1 medications. Women face substantially higher risk than men.

From the AWARD trial program (pooled analysis, Blonde et al., Diabetes, Obesity and Metabolism 2018):

• Total gallbladder-related adverse events: 2.7% of all patients
• Female patients: 4.1% incidence
• Male patients: 1.8% incidence
• Female-to-male risk ratio: 2.3:1

Of the 94 gallstone cases reported across AWARD trials, 88 occurred in women (94%).

The mechanism has two components:

Rapid weight loss. GLP-1 medications cause rapid weight loss in the first 12 to 20 weeks. Rapid fat mobilization increases cholesterol secretion into bile. When cholesterol concentration exceeds bile acid capacity to solubilize it, cholesterol crystals precipitate and form gallstones. This risk exists for anyone losing weight rapidly, but women have higher baseline gallstone prevalence (10% to 15% versus 5% to 8% in men).

Estrogen effect on bile composition. Estrogen increases cholesterol saturation in bile and reduces bile acid synthesis. Premenopausal women and women on estrogen-containing contraceptives or hormone replacement therapy have higher baseline lithogenic (stone-forming) bile. Adding rapid weight loss on top of this baseline creates a perfect storm.

The risk is highest during months 3 to 6 of treatment when weight loss is most rapid. Most cases present as biliary colic (severe right-upper-quadrant pain after meals, especially fatty meals) or acute cholecystitis (gallbladder inflammation).

Prevention protocol for high-risk women:

• Women with prior gallbladder symptoms, family history of gallstones, or obesity (BMI over 35) should discuss baseline ultrasound screening
• Gradual dose titration (staying at 0.75 mg for 6 to 8 weeks before escalating to 1.5 mg) may reduce rapid weight loss velocity
• Maintain fat intake at 20% to 30% of calories (very low-fat diets paradoxically increase gallstone risk by reducing gallbladder contraction frequency)
• Report right-upper-quadrant pain, nausea after fatty meals, or pain radiating to the right shoulder immediately

Menstrual cycle changes and hormonal interactions

Menstrual irregularities are an under-reported side effect in the published literature but consistently appear in post-marketing surveillance and patient forums. The AWARD trials did not systematically track menstrual changes, so the data comes from secondary analyses and real-world observation.

A 2023 post-marketing analysis from the FDA Adverse Event Reporting System (FAERS) identified menstrual irregularities in 8.2% of premenopausal women on dulaglutide, with the following patterns:

• Irregular cycle length (cycles shorter than 21 days or longer than 35 days): 4.7%
• Heavier menstrual bleeding (menorrhagia): 2.1%
• Missed periods (amenorrhea) in non-pregnant women: 1.4%

The mechanism is indirect. GLP-1 receptors exist in the hypothalamus and pituitary, which regulate reproductive hormone secretion. Rapid weight loss itself disrupts the hypothalamic-pituitary-ovarian axis. Women with polycystic ovary syndrome (PCOS) sometimes see improved cycle regularity on GLP-1 medications due to improved insulin sensitivity, but women without PCOS more often see temporary disruption.

The pattern typically resolves within 12 to 16 weeks as weight loss stabilizes. Persistent amenorrhea beyond 16 weeks warrants evaluation to rule out pregnancy (GLP-1 medications improve fertility in some women with PCOS) or other causes.

Important note for women on hormonal contraceptives: Severe vomiting or diarrhea during Trulicity titration can reduce absorption of oral contraceptives. If vomiting occurs within 3 to 4 hours of taking a birth control pill, use backup contraception for the remainder of that cycle.

Injection site reactions: the pattern in female patients

Injection site reactions (redness, itching, swelling, or lumps at the injection site) occur in approximately 4% to 6% of Trulicity patients. The sex difference is modest but real: 5.8% in women versus 4.1% in men in the pooled AWARD data.

The likely explanation is subcutaneous fat distribution. Women have thicker subcutaneous fat layers in typical injection sites (abdomen, thigh, upper arm), which may affect medication dispersion and local immune response.

The reactions are typically mild and resolve within 48 to 72 hours. Persistent nodules lasting more than 2 weeks or spreading redness suggest lipohypertrophy (fat tissue buildup from repeated injections in the same spot) or, rarely, infection.

Injection site management specific to female anatomy:

• Rotate injection sites in a systematic pattern (different quadrant of abdomen each week, or alternate between abdomen and thigh)
• Avoid injecting within 2 inches of the belly button, which has denser nerve endings and higher reaction rates in women
• For women with higher body fat percentage, ensure the needle fully penetrates the subcutaneous layer (the Trulicity pen is designed for this, but very lean women may need to pinch skin)
• Apply ice for 30 to 60 seconds before injection to reduce pain perception
• Avoid injecting into areas with stretch marks, which have altered collagen structure and slower absorption

Hypoglycemia risk in women with and without diabetes

Trulicity carries low intrinsic hypoglycemia risk when used alone because it's glucose-dependent (it only stimulates insulin when blood sugar is elevated). However, women face different hypoglycemia patterns than men when Trulicity is combined with other diabetes medications.

In the AWARD-2 trial (dulaglutide plus metformin, N = 807):

• Hypoglycemia rate in women: 3.2%
• Hypoglycemia rate in men: 2.1%

In the AWARD-9 trial (dulaglutide plus SGLT2 inhibitor, N = 300):

• Hypoglycemia rate in women: 4.7%
• Hypoglycemia rate in men: 3.1%

The difference is most pronounced in women over 60, likely due to age-related changes in counter-regulatory hormone response (glucagon and epinephrine secretion in response to low blood sugar declines with age and is lower in older women than older men).

For women without diabetes using compounded dulaglutide for weight loss, symptomatic hypoglycemia is rare (under 1%) but can occur during periods of inadequate calorie intake combined with exercise. Women report shakiness, sweating, confusion, and irritability.

Hypoglycemia prevention in women:

• Women on sulfonylureas (glipizide, glyburide) or insulin should expect dose reductions within the first 4 to 8 weeks of Trulicity
• Carry glucose tablets or a small carbohydrate source during exercise
• Recognize that menstrual cycle affects insulin sensitivity (higher sensitivity during follicular phase, lower during luteal phase), which can create variable blood sugar patterns
• Test blood sugar if symptoms occur; treat with 15 grams of fast-acting carbohydrate if below 70 mg/dL

What most articles get wrong about female side effects

Most patient-facing articles on Trulicity side effects either ignore sex differences entirely or mention them in passing without explaining the mechanism or clinical relevance. The most common error is conflating correlation with causation in the gallbladder data.

The error: "Women are more likely to develop gallstones on Trulicity because the medication affects female hormones."

Why it's wrong: Trulicity does not directly alter estrogen or progesterone levels. The gallstone risk comes from rapid weight loss (which increases cholesterol in bile) combined with women's higher baseline gallstone prevalence and estrogen's pre-existing effect on bile composition. The medication doesn't cause the hormonal effect; it adds rapid weight loss on top of an existing hormonal predisposition.

The correct framing: Women have higher baseline gallstone risk due to estrogen. Rapid weight loss from any cause (GLP-1 medications, bariatric surgery, very low-calorie diets) increases gallstone formation. The combination of female sex plus rapid GLP-1-induced weight loss creates multiplicative risk, not additive risk.

This distinction matters for clinical decision-making. A woman with prior gallbladder symptoms should discuss the risk before starting Trulicity. A woman with no risk factors doesn't need to avoid the medication out of fear of gallstones, but she should know the warning signs and report symptoms early.

The second common error is overstating the menstrual irregularity risk. Patient forums and some telehealth blogs claim "most women" experience cycle changes on Trulicity. The actual rate is 8% to 10%, and most cases resolve within 16 weeks. Overstating the risk creates unnecessary anxiety and may deter women from effective treatment.

The step-by-step protocol for managing female-specific symptoms

This protocol addresses the symptoms women report most frequently. Start at step 1 for each symptom category. Escalate only if symptoms persist after 7 to 10 days at each step.

For nausea and vomiting:

Step 1: Dietary modification

• Eat 5 to 6 small meals instead of 3 large ones
• Emphasize bland, low-fat, protein-rich foods (chicken, fish, eggs, Greek yogurt)
• Avoid lying down within 2 hours of eating
• Ginger tea or ginger chews (1 gram per day) reduce nausea in 60% of women in published studies
• Track symptoms relative to menstrual cycle; if nausea worsens during luteal phase, reduce meal size during that window

Step 2: Over-the-counter anti-nausea medication

• Vitamin B6 (pyridoxine) 25 mg three times daily
• Doxylamine 12.5 mg at bedtime (this is the combination used for pregnancy-related nausea and is safe for non-pregnant women)
• Dramamine (dimenhydrinate) 50 mg every 6 hours as needed

Step 3: Prescription anti-nausea medication

• Ondansetron (Zofran) 4 mg every 8 hours as needed
• Metoclopramide (Reglan) 10 mg before meals (use cautiously; can worsen depression in susceptible individuals)
• Promethazine (Phenergan) 12.5 to 25 mg every 6 hours

Step 4: Dose adjustment

• If nausea is severe and persistent despite step 3, discuss staying at 0.75 mg instead of escalating to 1.5 mg
• Some women achieve adequate weight loss and glycemic control at the lower dose with better tolerability

For menstrual irregularities:

Step 1: Observation and tracking

• Track cycle length, flow intensity, and symptoms for 3 cycles
• Most irregularities resolve by cycle 4 to 6 after starting Trulicity
• Rule out pregnancy with a home test if periods stop

Step 2: Iron supplementation if bleeding is heavy

• Ferrous sulfate 325 mg daily if menorrhagia causes fatigue or documented low ferritin
• Recheck hemoglobin and ferritin at 8 weeks

Step 3: Provider evaluation if irregularities persist beyond 16 weeks

• Pelvic ultrasound to rule out structural causes
• Hormone panel (FSH, LH, estradiol, progesterone) if amenorrhea persists
• Consider temporary discontinuation if cycle disruption is severe and affecting quality of life

For injection site reactions:

Step 1: Injection technique optimization

• Rotate sites systematically (keep a written log if needed)
• Clean skin with alcohol and let it dry completely before injecting (wet alcohol increases sting)
• Inject at room temperature (take pen out of refrigerator 30 minutes before injection)
• Don't rub the site after injection

Step 2: Topical management

• Ice pack for 1 to 2 minutes before injection
• Hydrocortisone 1% cream applied to site after injection if redness develops
• Oral antihistamine (cetirizine 10 mg or loratadine 10 mg) daily if itching is prominent

Step 3: Provider evaluation if reactions worsen

• Persistent nodules, spreading redness, or warmth may indicate infection or lipohypertrophy
• Switch to a different injection site (abdomen to thigh, or vice versa)
• Rarely, switching to a different GLP-1 medication is needed

When symptoms signal something more serious

Most side effects are uncomfortable but not dangerous. The following symptoms require same-day or emergency evaluation:

Same-day provider contact:

• Severe right-upper-quadrant abdominal pain, especially after eating (possible gallbladder disease)
• Persistent vomiting for more than 24 hours (risk of dehydration and electrolyte imbalance)
• Severe upper abdominal pain radiating to the back (possible pancreatitis; rare but serious)
• Visual changes, severe headache, or confusion (possible hypoglycemia if on other diabetes medications)
• Menstrual bleeding soaking through a pad or tampon every hour for 2+ hours (possible menorrhagia requiring intervention)

Emergency care (call 911 or go to ER):

• Severe allergic reaction (throat swelling, difficulty breathing, widespread hives)
• Severe abdominal pain with fever and vomiting (possible acute cholecystitis or pancreatitis)
• Chest pain or pressure (GLP-1 medications reduce cardiovascular risk, but chest pain always warrants evaluation)
• Sudden severe headache, vision loss, or one-sided weakness (rule out stroke, especially in women with migraine history or on estrogen-containing contraceptives)
• Suicidal thoughts (GLP-1 medications are not causally linked to suicide, but rapid weight change can affect mood in susceptible individuals)

The threshold for calling a provider should be lower for women who are pregnant or trying to conceive. Trulicity is contraindicated in pregnancy, and any woman of reproductive age on Trulicity should use reliable contraception.

The dose-response question in women

The standard Trulicity dosing is 0.75 mg weekly for 4 weeks, then 1.5 mg weekly for maintenance. Some patients escalate to 3 mg or 4.5 mg for additional weight loss or glycemic control.

The published data shows a clear dose-response relationship for both efficacy and side effects, but the slope differs between women and men.

Weight loss at 40 weeks (AWARD-1 trial):

Dose	Female weight loss	Male weight loss
0.75 mg weekly	2.8 kg (6.2 lbs)	2.1 kg (4.6 lbs)
1.5 mg weekly	3.6 kg (7.9 lbs)	2.9 kg (6.4 lbs)

Women lose slightly more weight than men at equivalent doses, likely due to higher GLP-1 receptor density in adipose tissue.

Nausea at 1.5 mg vs 0.75 mg (pooled AWARD data):

Dose	Female nausea rate	Male nausea rate
0.75 mg	14.2%	9.8%
1.5 mg	21.2%	14.8%

The dose escalation increases nausea by roughly 50% in both sexes, but women start from a higher baseline.

Clinical implication: Women who have severe nausea at 0.75 mg should expect worsening at 1.5 mg. The conservative approach is to stay at 0.75 mg for 8 to 12 weeks instead of the standard 4 weeks, allowing full adaptation before escalating. Some women achieve their weight loss and glycemic goals at 0.75 mg and never need to escalate.

The pattern we observe in FormBlends patients is that women over 50 or with BMI under 32 often do well at 0.75 mg long-term, while younger women or those with BMI over 35 more often need 1.5 mg for adequate appetite suppression.

Pregnancy, breastfeeding, and fertility considerations

Trulicity is contraindicated in pregnancy. Animal studies showed fetal harm (skeletal abnormalities and growth restriction) at doses equivalent to human therapeutic doses. The FDA classifies it as pregnancy category C (risk cannot be ruled out).

Pre-pregnancy planning:

• Discontinue Trulicity at least 8 weeks before attempting conception (the medication's half-life is 5 days, but allowing 8 weeks ensures complete washout and metabolic stabilization)
• Women with diabetes should transition to insulin or metformin (both safe in pregnancy) under provider supervision
• Weight lost on Trulicity before pregnancy is maintained in most women if healthy eating habits continue

Unplanned pregnancy:

• Stop Trulicity immediately upon positive pregnancy test
• Contact your provider the same day for transition planning
• First-trimester exposure has limited human data; most case reports show normal outcomes, but the theoretical risk remains

Breastfeeding:

• No human data on dulaglutide passage into breast milk
• The large molecular size (63 kDa) suggests minimal transfer, but this is theoretical
• Most providers recommend avoiding Trulicity during breastfeeding and using it only after weaning

Fertility effects:

• Women with PCOS often see improved ovulation and fertility on GLP-1 medications due to improved insulin sensitivity
• Women without PCOS may see temporary cycle disruption (as discussed earlier), but this does not indicate reduced fertility
• Use reliable contraception while on Trulicity unless actively planning pregnancy with provider guidance

FAQ

Do women experience worse side effects on Trulicity than men? Yes, for specific side effects. Women report higher rates of nausea (21% vs 15%), vomiting, and gallbladder complications. The difference is driven by slower baseline gastric emptying, hormonal effects on GI motility, and higher baseline gallstone prevalence in women.

Why does Trulicity cause more nausea in women? Women have 20% to 30% slower gastric emptying than men at baseline. Trulicity slows emptying further, and the compounding effect is more pronounced in women. Hormonal fluctuations during the menstrual cycle also affect nausea thresholds.

Can Trulicity affect my menstrual cycle? Yes, about 8% of premenopausal women experience irregular cycles, heavier bleeding, or missed periods during the first 12 weeks of treatment. Most cases resolve by week 16 as weight loss stabilizes. Persistent changes beyond 16 weeks warrant evaluation.

Is gallbladder disease common in women on Trulicity? Gallbladder complications occur in about 4% of women on Trulicity, compared to 1.8% of men. The risk is highest during rapid weight loss in months 3 to 6 of treatment. Women with prior gallbladder symptoms or family history face higher risk.

Should I start Trulicity at a certain time in my menstrual cycle? Starting during the follicular phase (days 1 to 10 of your cycle) may reduce initial nausea intensity compared to starting during the luteal phase, when progesterone slows GI motility. This is based on clinical observation, not controlled trials.

Can I take Trulicity if I'm on birth control pills? Yes, Trulicity does not interact with hormonal contraceptives. However, severe vomiting or diarrhea can reduce absorption of oral contraceptives. Use backup contraception if vomiting occurs within 3 to 4 hours of taking your pill.

Will Trulicity affect my ability to get pregnant? Trulicity may improve fertility in women with PCOS by improving insulin sensitivity and promoting ovulation. It does not reduce fertility in women without PCOS, though temporary menstrual irregularities can occur. Stop Trulicity at least 8 weeks before attempting conception.

Can I use Trulicity while breastfeeding? No human data exists on dulaglutide in breast milk. Most providers recommend avoiding it during breastfeeding. Discuss timing of resumption after weaning with your provider.

Do I need a lower dose of Trulicity because I'm female? Current dosing guidelines do not differentiate by sex. However, some women achieve adequate weight loss and symptom control at 0.75 mg weekly without escalating to 1.5 mg. Discuss individualized dosing with your provider based on response and tolerability.

What should I do if I get severe nausea on Trulicity? Start with dietary changes (small frequent meals, bland foods, ginger). If symptoms persist after 7 days, add vitamin B6 and doxylamine. If still severe, contact your provider about prescription anti-nausea medication or staying at a lower dose.

Can Trulicity cause weight gain in women? No. Weight gain is not a reported side effect. The average weight loss in women at 40 weeks is 3.6 kg (7.9 lbs) at the 1.5 mg dose. If weight gain occurs, evaluate for other causes (thyroid dysfunction, medication changes, dietary changes).

Is it safe to use Trulicity during perimenopause? Yes. Perimenopausal women in clinical trials showed similar efficacy and safety profiles to premenopausal women. Hot flashes and other perimenopausal symptoms are not worsened by Trulicity. Some women report improved metabolic parameters (insulin sensitivity, lipids) that benefit cardiovascular health during the menopausal transition.

Sources

1. Bennink R et al. Evaluation of gastric emptying in men and women using a standardized radiolabeled meal. Neurogastroenterology & Motility. 1998.
2. Blonde L et al. Gastrointestinal tolerability of dulaglutide: pooled analysis of data from the AWARD phase 3 clinical trial program. Diabetes, Obesity and Metabolism. 2018.
3. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019.
4. Nauck MA et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014.
5. Weinberg M et al. Sex differences in gastric emptying and postprandial symptoms. American Journal of Gastroenterology. 2020.
6. Wysham C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014.
7. FDA Adverse Event Reporting System (FAERS) data on dulaglutide menstrual irregularities. 2023.
8. Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015.
9. Ludvik B et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2018.
10. Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
11. Dungan KM et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. 2014.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
14. Matthews DR et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Zofran, Reglan, Phenergan, and Dramamine are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.